Zoono Group Limited (ZOONF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Zoono Group Limited (ZOONF) trades at $0.04 with AI Score 39/100 (Grade D). Zoono Group Limited researches, develops, and sells antimicrobial products globally. Market cap: $18.08M, Sector: Consumer defensive.
Last analyzed: Mar 16, 2026Analyst Coverage for ZOONF: ZOONF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ZOONF against Consumer Defensive peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ZOONF: 1/1 perspectives are bearish.
Zoono Group Limited (ZOONF) Consumer Business Overview
Zoono Group Limited develops and markets antimicrobial solutions across diverse sectors like healthcare and transportation. Operating internationally from New Zealand, the company faces profitability challenges, reflected in its negative profit and gross margins, while navigating a competitive landscape of hygiene and sanitization product providers.
What Is the Investment Thesis for ZOONF?
Investing in Zoono Group Limited presents a high-risk, high-reward scenario. The company's innovative antimicrobial technology has the potential to disrupt the hygiene and sanitization market. However, its current financial performance, characterized by a negative profit margin of -369.4% and a negative gross margin of -74.6%, raises concerns about its ability to achieve sustainable profitability. The company's beta of 1.37 suggests higher volatility compared to the market. Growth catalysts include expanding into new markets and developing new applications for its technology. The key risk is whether Zoono can improve its financial performance and achieve profitability in the face of intense competition and operational challenges. Investors should closely monitor the company's revenue growth, cost management, and progress in achieving profitability.
Based on FMP financials and quantitative analysis
ZOONF Key Highlights
- Market Cap of $0.00B indicates a micro-cap company with high growth potential but also higher risk.
- P/E ratio of -6.04 reflects current losses, suggesting the company's earnings are negative.
- Profit Margin of -369.4% indicates significant challenges in achieving profitability.
- Gross Margin of -74.6% shows that the cost of goods sold exceeds revenue, requiring immediate attention to cost management.
- Beta of 1.37 suggests the stock is more volatile than the market average, implying higher risk.
Who Are ZOONF's Competitors?
ZOONF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DIDAF Distribuidora Internacional de Alimentación, S.A. | $21.60 | +0.00% | $1.25B | 44 |
| HKHC Horizon Kinetics Holding Corporation | $27.01 | -3.54% | $503.34M | 60 |
| FACYF Fancl Corporation | $17.45 | +0.00% | $2.37B | 63 |
| SGI Somnigroup International Inc | $72.67 | +0.48% | $15.28B | 62 |
| ELF e.l.f. Beauty, Inc. | $60.68 | +4.40% | $3.61B | 59 |
| MIOFF Milbon Co., Ltd. | $52.60 | +0.00% | $1.71B | 58 |
| KCDMF Kimberly-Clark de México, S. A. B. de C. V. | $2.10 | -3.67% | $6.30B | 48 |
| PG The Procter & Gamble Company | $148.32 | -0.49% | $345.38B | 48 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ZOONF's Key Strengths?
- Proprietary antimicrobial technology.
- Long-lasting protection.
- Diverse product range.
- Established international presence.
What Are ZOONF's Weaknesses?
- Negative profit margin.
- Negative gross margin.
- Limited brand awareness.
- High volatility.
What Could Drive ZOONF Stock Higher?
- Expansion into new geographic markets, targeting regions with high demand for hygiene products.
- Development of new applications for its antimicrobial technology in sectors like food safety and agriculture.
- Strategic partnerships and collaborations with established players in healthcare, hospitality, and transportation.
- Increased brand awareness and marketing efforts to attract new customers.
- Product innovation and development to maintain a competitive edge.
What Are the Key Risks for ZOONF?
- Intense competition from established players in the hygiene and sanitization market.
- Changing consumer preferences and demand for alternative hygiene solutions.
- Regulatory changes impacting the sale and use of antimicrobial products.
- Economic downturn affecting consumer spending and business investment.
- Negative profit and gross margins indicating financial instability.
What Are the Growth Opportunities for ZOONF?
- Growth opportunity 1: Expanding into new geographic markets represents a significant growth opportunity for Zoono. By targeting regions with high demand for hygiene products, such as Asia-Pacific and Latin America, the company can increase its revenue streams. The global hygiene market is projected to reach billions of dollars in the coming years, providing a substantial market opportunity for Zoono's antimicrobial solutions. Timeline: Within the next 2-3 years.
- Growth opportunity 2: Developing new applications for its antimicrobial technology can drive growth for Zoono. This includes exploring applications in areas such as food safety, agriculture, and water treatment. By diversifying its product offerings, Zoono can reduce its reliance on existing markets and tap into new revenue streams. The market for antimicrobial solutions in these sectors is substantial and growing. Timeline: Ongoing.
- Growth opportunity 3: Strategic partnerships and collaborations with other companies can accelerate Zoono's growth. By partnering with established players in the healthcare, hospitality, and transportation sectors, Zoono can gain access to new markets and distribution channels. These partnerships can also provide Zoono with valuable resources and expertise. Timeline: Ongoing.
- Growth opportunity 4: Increasing brand awareness and marketing efforts can drive sales growth for Zoono. By investing in marketing campaigns and promoting the benefits of its antimicrobial technology, Zoono can attract new customers and increase its market share. This includes utilizing digital marketing channels, social media, and public relations. Timeline: Ongoing.
- Growth opportunity 5: Focusing on product innovation and development can help Zoono maintain a competitive edge. By continuously improving its antimicrobial technology and developing new products, Zoono can meet the evolving needs of its customers and stay ahead of the competition. This includes investing in research and development and collaborating with universities and research institutions. Timeline: Ongoing.
What Opportunities Does ZOONF Have?
- Expanding into new geographic markets.
- Developing new applications for its technology.
- Strategic partnerships and collaborations.
- Increasing brand awareness and marketing efforts.
What Threats Does ZOONF Face?
- Intense competition.
- Changing consumer preferences.
- Regulatory changes.
- Economic downturn.
What Are ZOONF's Competitive Advantages?
- Proprietary antimicrobial technology provides a unique selling proposition.
- Long-lasting protection differentiates Zoono from traditional sanitizers.
- Diverse range of applications across multiple sectors reduces reliance on a single market.
- Established presence in New Zealand and international markets provides a foundation for growth.
What Does ZOONF Do?
Zoono Group Limited, established in 1986 and headquartered in Auckland, New Zealand, focuses on the research, development, and sale of antimicrobial products. The company's portfolio includes hand sanitizers, textile applicators, mould remediation solutions, and surface sanitizers. These products cater to a wide array of sectors, including airlines, healthcare facilities, childcare centers, facilities management companies, transportation services, educational institutions, and the hospitality industry. Zoono's core offering revolves around providing long-lasting antimicrobial protection, differentiating itself from conventional sanitizers that offer only short-term efficacy. The company operates both in New Zealand and internationally, seeking to establish a global presence in the antimicrobial solutions market. Despite its innovative product range, Zoono faces challenges in achieving profitability, as reflected in its negative profit and gross margins. The company continues to explore new applications for its technology and expand its market reach.
What Products and Services Does ZOONF Offer?
- Researches and develops antimicrobial products.
- Sells hand sanitizers for personal hygiene.
- Offers textile applicators for long-lasting protection on fabrics.
- Provides mould remediation solutions for homes and businesses.
- Markets surface sanitizers for various environments.
- Serves diverse sectors including healthcare, transportation, and education.
How Does ZOONF Make Money?
- Develops and manufactures antimicrobial formulations.
- Sells products directly to businesses and consumers.
- Distributes products through partnerships and distributors.
- Generates revenue through product sales.
What Industry Does ZOONF Operate In?
Zoono Group Limited operates within the global household and personal products industry, which has seen increased demand for hygiene and sanitization products, particularly in the wake of recent global health events. The market is competitive, with established players like BTTUF (Byotrol plc) and GCEH competing for market share. The industry is driven by increasing consumer awareness of hygiene and health, as well as regulatory standards for cleanliness in various sectors. Zoono aims to differentiate itself through its long-lasting antimicrobial technology. The company's success depends on its ability to effectively market its products and compete with larger, more established players.
Who Are ZOONF's Key Customers?
- Airlines seeking to sanitize cabins and protect passengers.
- Healthcare facilities needing to maintain sterile environments.
- Childcare centers focused on preventing the spread of germs.
- Facilities management companies responsible for cleaning and sanitizing buildings.
- Transportation services aiming to provide a safe and hygienic environment for travelers.
ZOONF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in Zoono's growth prospects, suggesting that key stakeholders believe in the company's future.
- Community sentiment has shifted positively as discussions around Zoono's innovative antimicrobial products gain traction, highlighting their relevance in health and safety.
- Zoono's partnerships with various industries are strengthening its market presence, creating optimism about expanding its customer base.
- The increasing global focus on hygiene and sanitation due to health concerns is positioning Zoono favorably in a growing market.
Bear Case
- Concerns over Zoono's reliance on a niche market could limit its growth potential, making investors wary of long-term sustainability.
- Community discussions reveal skepticism about the scalability of Zoono's products, with some questioning their effectiveness compared to competitors.
- Recent regulatory challenges in the health sector may pose risks to Zoono's operations, creating uncertainty among investors.
- Market perception remains cautious as Zoono's financial performance has not consistently met expectations, leading to doubts about its ability to compete.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ZOONF Latest News
-
Insider Stock Buying Reaches NZ$1.35m On Zoono Group
Yahoo! Finance: ZOONF News · May 6, 2026
ZOONF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ZOONF.
Price Targets
Wall Street price target analysis for ZOONF.
ZOONF MoonshotScore
What does this score mean?
The MoonshotScore rates ZOONF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Paul Hyslop
CEO
Paul Hyslop serves as the CEO of Zoono Group Limited. Information regarding his detailed career history, education, and previous roles is not available in the provided data. Without additional context, a comprehensive background profile cannot be constructed.
Track Record: Information regarding Paul Hyslop's specific achievements, strategic decisions, and company milestones under his leadership is not available in the provided data. Therefore, a detailed assessment of his track record cannot be provided.
ZOONF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Zoono Group Limited may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower liquidity can lead to price volatility.
- Potential for fraud or manipulation is higher in the OTC market.
- OTC stocks may not be subject to the same regulatory oversight as exchange-listed stocks.
- The 'OTC Other' designation indicates a higher risk profile.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's revenue and earnings growth potential.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Company has been in operation since 1986.
- Products are sold internationally.
- Serves various sectors including healthcare and transportation.
- Has a CEO and leadership team in place.
Common Questions About ZOONF (Consumer Defensive)
What does Zoono Group Limited do?
Zoono Group Limited is engaged in the research, development, and sale of antimicrobial products. Its offerings include hand sanitizers, textile applicators, mould remediation solutions, and surface sanitizers. These products cater to various sectors, including airlines, healthcare, childcare, facilities management, transportation, education, and hospitality. Zoono's core value proposition lies in providing long-lasting antimicrobial protection, setting it apart from conventional sanitizers with short-term efficacy. The company operates both in New Zealand and internationally, aiming to establish a global presence in the antimicrobial solutions market.
What do analysts say about ZOONF stock?
There is currently no available analyst coverage or consensus for ZOONF stock due to its OTC listing and limited market capitalization. Investors should conduct their own thorough research and due diligence before making any investment decisions. Key valuation metrics, such as price-to-earnings ratio, are currently negative, reflecting the company's losses. Growth considerations include the company's ability to expand into new markets, develop new applications for its technology, and improve its financial performance.
What are the main risks for ZOONF?
Zoono Group Limited faces several risks, including intense competition from established players in the hygiene and sanitization market, changing consumer preferences, regulatory changes, and economic downturns. The company's negative profit and gross margins also pose a significant risk to its financial stability. As an OTC-listed stock, ZOONF is subject to additional risks, such as limited financial disclosure, lower liquidity, and potential for fraud or manipulation. Investors should carefully consider these risks before investing in ZOONF.
What are the key factors to evaluate for ZOONF?
Zoono Group Limited (ZOONF) holds an AI score of 39/100 (low). Not financial advice.
How frequently does ZOONF data refresh on this page?
ZOONF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ZOONF's recent stock price performance?
Zoono Group Limited (ZOONF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary antimicrobial technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZOONF overvalued or undervalued right now?
Valuing Zoono Group Limited (ZOONF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ZOONF?
Before investing in Zoono Group Limited (ZOONF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for OTC-listed companies.
- Financial data is based on available reports and may not be fully comprehensive.
- AI analysis pending for ZOONF.